Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.50 |
| ▸ | DRD1 | P21728 | 5/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Embramine SCHEMBL1650532 | 0.98 | CHRM2 (0.59) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Moxastine SCHEMBL29281 | 0.90 | CHRM2 (0.71) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Chlorphenoxamine SCHEMBL29208 | 0.84 | CHRM2 (0.61) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| SCHEMBL21665812 | 0.83 | CHRM2 (0.44) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Chlorphenoxamine SCHEMBL125112 | 0.83 | CHRM2 (0.59) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Chlorphenoxamine SCHEMBL1649036 | 0.82 | CHRM2 (0.62) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Doxylamine SCHEMBL12959067 | 0.76 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Doxylamine SCHEMBL30702275 | 0.76 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Doxylamine SCHEMBL30116312 | 0.76 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM1SLC6A2 | |
| Doxylamine SCHEMBL4709 | 0.76 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-05 | — | — | US | claimed |
| US-12263168-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-04-01 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12251469-B2 | Sterically stabilized carrier compositions for treating a mammal | VGSK TECHNOLOGIES, INC. (US) | 2025-03-18 | — | — | US | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| US-20240299292-A1 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-12 | — | — | US | claimed |
| EP-4412602-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | Tonix Pharmaceuticals Holding Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2024124023-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007026151-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2007-03-08 | — | — | WO | claimed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | claimed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | claimed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | CHRM2 145/4885CYP2D6 785/4885BLM 1779/4885 |
| US-12263168-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | CA2, CMA1, CPA3 | CHRM2 3597/4885CYP2D6 3352/4885BLM 4870/4885 |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | CHRM2 3597/4885CYP2D6 3352/4885BLM 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.